Medigen Vaccine Biologics Corp (高端疫苗) would cooperate with the US National Institutes of Health to develop a vaccine against COVID-19, the company said yesterday, adding that it plans to begin animal testing in the second quarter of this year.
The Hsinchu-based company on Sunday signed an agreement with the US agency, which is to provide a vaccine candidate and the viral spike protein to Medigen for testing and development, spokesman Leo Lee (李思賢) told a news conference in Taipei.
Medigen Vaccine would use recombinant spike protein technology to develop the vaccine, Lee said.
Photo: Kao Shih-ching, Taipei Times
The agency last month partnered with US-based Moderna Inc to develop a vaccine utilizing messenger RNA technology.
Medigen Vaccine would inject the spike protein-based vaccine candidate into rats to observe their immunogenicity and examine whether the vaccine prototype is safe, Lee said.
While animal testing for vaccine development normally takes four to six months, the firm plans to finish the tests before the end of June to speed up the process, he added.
It then plans to apply to the Food and Drug Administration (FDA) to run a double-blind clinical test in the second half of this year, concentrating on the vaccines’ efficacy and safety, he added.
The company would not conduct human trials on infected people, but on healthy volunteers, vice chairman Charles Chen (陳燦堅) said.
“It will not be accurate to run preliminary tests on infected people. As patients’ immune systems would create antibodies, we would not know whether their recovery is attributable to their own antibodies or the vaccine’s,” Chen said.
The number of volunteers and the duration of the tests would be determined by FDA regulations, he said.
“The government might allow us to speed up the process and recruit fewer volunteers, but we expect to at least complete phase one tests or combine phase one and two tests to save time,” Chen said.
If the vaccine is proven effective, Medigen Vaccine expects to manufacture and sell it in Taiwan and neighboring countries, Chen added.
Chen, who discussed the cooperation with the US agency before the Lunar New Year holiday, said the two sides have been producing dengue vaccines since 2016.
Compared with the regular development of vaccines, the research and development costs for a vaccine against COVID-19 would be much lower due to the US agency’s resources, Medigen Vaccine financial director Jade Yang (楊郁萍) said.
Shares of Medigen Vaccine jumped 9.97 percent to close at NT$35.85 in Taipei trading yesterday.
VALUABLE STOCK: The company closed at NT$1,005 a share, on demand for AI and HPC chips, and is expected to issue a positive report during its earnings conference Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) shares rose 2.66 percent to close at a record high of NT$1,005 yesterday. as investors expect the company to continue benefiting from strong demand for artificial intelligence (AI) and high-performance computing (HPC) chips. TSMC is the 19th member of the local bourse’s NT$1,000 stock club, which includes smartphone chip designer MediaTek Inc (聯發科) and electric transformer manufacturer Fortune Electric Co (華城電機). Yesterday’s rally swelled TSMC’s market capitalization to NT$26.06 trillion (US$802.3 billion) and contributed about 211 points to the TAIEX, which closed up 350.1 points, or 1.51 percent, to 23,522.53, another record high, Taiwan Stock
Luxgen Motor Co (納智捷汽車), a subsidiary of Yulon Motor Co (裕隆汽車), yesterday said it is again offering a NT$100,000 discount for its entry-level n7 electric vehicle models. The n7’s price has gone down from NT$1.099 million to NT$999,000, Luxgen said, adding that there are 25,000 preorders for the model. MG Motor’s electric hatchback, the MG4, entered the market in the middle of last month, with a starting price of NT$990,000. China Motor Corp (中華汽車), which distributes MG vehicles in Taiwan, said it aims to sell 1,600 MG4s this year. MG, originally a British brand, was acquired by China’s SAIC Motor
South Korea’s SK Hynix Inc, the world’s No. 2 memorychip maker, is to invest 103 trillion won (US$74.6 billion) through 2028 to strengthen its chips business, focusing on artificial intelligence (AI), its parent SK Group said yesterday. SK Group also said it plans to secure 80 trillion won by 2026 to invest in AI and semiconductors as well as fund shareholder returns, while streamlining its more than 175 subsidiaries. The sprawling conglomerate outlined the plans following a two-day strategy meeting, aiming to revive the group after SK Hynix, its main money maker, and the group’s electric vehicle battery arm suffered heavy losses. SK
Google on Monday said it is planning to invest in New Green Power Co (NGP, 永鑫能源), a solar energy developer owned by BlackRock Inc, to build 1 gigawatt of solar capacity in Taiwan to supply clean energy for its local data center and offices. “Our investment in NGP, subject to regulatory approval, will serve as development capital toward its 1 GW pipeline of new solar projects, catalyzing critical equity and debt financing for those projects,” Google’s Data Center Energy global head Amanda Peterson Corio wrote on a company blog. It did not disclose financial details. “We expect to procure up to 300 megawatts